[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Madanur MA, Battula N, Azam MO, Heaton N, Rela M: Chylous ascites after pancreatico-duodenectomy cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):416-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chylous ascites (CA) following pancreatico-duodenectomy (PD) is a rare complication secondary to disruption of the lymphatics during extended retroperitoneal lymph node dissection.
  • The majority of cases do not develop CA, possibly due to patency of the proximal thoracic duct and good collaterals.
  • CA may be due to a consequence of occult obstruction of the proximal thoracic duct by malignant infiltration or tumor embolus.
  • Two patients developed loco-regional recurrences at a median follow up of 8 months (range 6-10 months).
  • And the other was currently disease free at a 10-month follow up.
  • CONCLUSIONS: CA as an uncommon postoperative complication requires frequent paracentesis, prolonged hospital stay, and delayed adjuvant chemotherapy.
  • [MeSH-minor] Aged. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Transplantation. Peritoneum / metabolism. Postoperative Complications. Retrospective Studies

  • Genetic Alliance. consumer health - Chylous Ascites.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690041.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Akamatsu S, Tsukazaki H, Inoue K, Nishio Y: [Testicular cancer with inferior vena caval embolus causing pulmonary embolism following chemotherapy: a case report]. Hinyokika Kiyo; 2004 May;50(5):327-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular cancer with inferior vena caval embolus causing pulmonary embolism following chemotherapy: a case report].
  • A 21-year-old male presented with right scrotal discomfort.
  • Right high orchiectomy revealed non-seminoma and he was diagnosed with stage I non-seminoma.
  • Since acute myeloid leukemia (AML) was diagnosed incidentally, no adjuvant therapy was given and he received chemotherapy for AML.
  • One year later, he complained of lumbago and general malaise.
  • Computed tomography showed retroperitoneal lymph node swelling, inferior vena caval embolus distal to the hepatic vein, and multiple lung nodules.
  • Metastasis of testicular neoplasm was suspected and chemotherapy with Bleomycin, Etoposide, and Cisplatin was started.
  • On the fourth day of chemotherapy, the patient complained of sudden dyspnea and acutely went into shock.
  • Pulmonary embolism was diagnosed and an inferior vena cava filter was placed.
  • Chemotherapy was continued for four courses and the tumor showed complete remission.
  • He has been free of disease for 24 months.
  • In rare cases of testicular cancer with inferior vena caval embolus, the physician should be aware of the possibility of causing pulmonary embolism after chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Embolism / complications. Leukemia, Myeloid / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Pulmonary Embolism / etiology. Testicular Neoplasms / drug therapy. Vena Cava, Inferior
  • [MeSH-minor] Acute Disease. Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Male. Vena Cava Filters


3. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH: The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol; 2008 Aug;173(2):561-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype.
  • Inflammatory breast carcinoma (IBC) is a particularly lethal form of breast cancer characterized by exaggerated lymphovascular invasion, which is a phenotype recapitulated in our human xenograft MARY-X.
  • Because of the resemblance of the spheroids to the embryonal blastocyst and their resistance to traditional chemotherapy/radiotherapy, we hypothesized that the spheroids expressed a stem cell-like phenotype.
  • MARY-X spheroids expressed embryonal stem cell markers including stellar, rex-1, nestin, H19, and potent transcriptional factors, oct-4, nanog, and sox-2, which are associated with stem cell self-renewal and developmental potential.
  • The stem cell phenotype exhibited by MARY-X also was exhibited by the lymphovascular emboli of human IBC cases independent of their molecular subtype.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Cell Transformation, Neoplastic. Lymphatic Vessels / pathology. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Polarity. Female. Humans. Inflammation / metabolism. Inflammation / pathology. Mice. Neoplasm Transplantation. Signal Transduction. Spheroids, Cellular / metabolism. Spheroids, Cellular / pathology. Transplantation, Heterologous


Advertisement
4. Hoshimoto S, Hagiuda J, Igarashi N, Matsui H, Koyama Y, Miyakita M, Takanosu S: [A case of advanced gastric cancer with a tumor embolus in the portal vein successfully treated with TS-1 and CDDP]. Gan To Kagaku Ryoho; 2004 Jul;31(7):1079-81
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with a tumor embolus in the portal vein successfully treated with TS-1 and CDDP].
  • A 71-year-old man was admitted to our hospital in February 2002 with a diagnosis of advanced gastric cancer with a tumor embolus in the portal vein.
  • TS-1 (120 mg/day) was administered orally daily for 21 days, and CDDP (90 mg/day) was infused intravenously on day 8.
  • After 1 course of this regimen, medication was discontinued in accordance with the patient's request.
  • The patient was readmitted with a history of tarry stools in July 2003.
  • Despite no cancer treatment for almost 1.5 years, the primary lesion and the metastatic lymph nodes had decreased significantly in size and the tumor embolus in the portal vein had disappeared completely on the CT scan.
  • He was therefore treated with TS-1 alone (120 mg/day) under a 4-weeks-on and 2-weeks-off regimen.
  • After 1 course of TS-1 administered alone, the primary lesion showed a further significant decrease in size as viewed by GI endoscopy, and biopsies did not reveal any evidence of malignancy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplastic Cells, Circulating / pathology. Portal Vein / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Humans. Infusions, Intravenous. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15272589.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Zeni PT Jr, Blank BG, Peeler DW: Use of rheolytic thrombectomy in treatment of acute massive pulmonary embolism. J Vasc Interv Radiol; 2003 Dec;14(12):1511-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of rheolytic thrombectomy in treatment of acute massive pulmonary embolism.
  • PURPOSE: The 6-F Xpeedior (AngioJet; Possis Medical, Minneapolis, MN) rheolytic thrombectomy catheter (RTC) uses high velocity saline jets for thrombus aspiration, maceration, and evacuation, through the Bernoulli principle.
  • The purpose of this study was to evaluate the efficacy of thrombus removal using the RTC in patients with acute massive pulmonary embolism (PE).
  • MATERIALS AND METHODS: Seventeen patients (mean age, 51.7 + 16.6 years; range, 30-86 years; 9 men, 8 women) with massive PE initially diagnosed by computed tomography (CT) or VQ scan and confirmed by pulmonary angiography were treated with the RTC.
  • Six patients had contraindications to thrombolytic therapy.
  • One patient presented with renal cell carcinoma and tumor embolus as suspected cause of PE.
  • Treatment resulted in immediate angiographic improvement and initial relief of PE symptoms (improvement in dyspnea and oxygen saturation) in 16 of 17 patients.
  • One patient developed heart block during the procedure, and further treatment with the RTC was discontinued.
  • Bradycardia occurred in one patient (managed with lidocaine).
  • After thrombectomy, 10 patients received adjunctive reteplase thrombolysis for treatment of residual thrombus, and 12 received inferior vena cava (IVC) filters.
  • In the patient with renal cell carcinoma, histopathologic analysis of the evacuated material confirmed tumor origin of the embolism.
  • There were two deaths, both within 24 hours of treatment and secondary to PE.
  • One death occurred in a patient who had only minimal thrombus removal after treatment with the RTC and no thrombolysis.
  • The remaining 15 patients showed continued improvement in PE symptoms and were eventually discharged from the hospital with mean length of stay 10.3 + 6.5 days (range, 5-30 days).
  • Further evaluation in a larger cohort of patients is warranted to assess whether this treatment may offer an alternative or complement to thrombolysis or surgical thrombectomy.
  • [MeSH-major] Fibrinolytic Agents / therapeutic use. Pulmonary Embolism / drug therapy. Pulmonary Embolism / surgery. Thrombectomy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Catheterization / adverse effects. Catheterization / instrumentation. Catheterization / methods. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Vasc Interv Radiol. 2004 Sep;15(9):1024; author reply 1024 [15470786.001]
  • (PMID = 14654484.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents
  •  go-up   go-down


6. Dzieciuchowicz ŁS, Słowinski M, Brzeziński JJ, Kycler W: Tumor embolus due to uterine cancer. Med Sci Monit; 2009 Oct;15(10):CS155-157
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor embolus due to uterine cancer.
  • The purpose of this paper is to report a case of tumor embolus of a brachial artery.
  • CASE REPORT: A 64-year-old woman was referred for vascular surgery due to acute right upper-limb ischemia.
  • Because of an atypical appearance resembling fatty tissue, the embolic material was sent for microscopic examination that revealed carcinoma cells.
  • Chest X-ray and CT-guided biopsy showed previously unknown pulmonary metastasis.
  • In spite of chemotherapy, the patient died one year later due to progression of the neoplastic disease.
  • The literature and common features of tumor embolus are reviewed.
  • This may be the first reported case of tumor peripheral arterial embolus caused by endometrial adenocarcinoma CONCLUSIONS: Although tumor emboli are a rarely described cause of acute limb ischemia, pathological examination of the embolic material seems to be indicated, especially in patients with an unknown source of emboli and in every case of an atypical appearance.
  • [MeSH-major] Embolism / complications. Embolism / pathology. Uterine Neoplasms / complications. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789516.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


7. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL: Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res; 2006 May 15;12(10):3124-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the safety and efficacy of bevacizumab and weekly docetaxel as first- or second-line therapy in patients with metastatic breast cancer (MBC).
  • PATIENTS AND METHODS: Twenty-seven MBC patients received i.v. bevacizumab at 10 mg/kg on days 1 and 15 in combination with i.v. docetaxel 35 mg/m2 on days 1, 8, and 15 of a 28-day cycle.
  • Primary end points were to assess toxicity, overall response rate, and progression-free survival.
  • RESULTS: One-hundred fifty-eight treatment cycles were administered with a median of six cycles (range 1-15 cycles) per patient.
  • The most common grade 4 toxicities per patient were as follows: 2 (7%)-pulmonary embolus, 1 (4%)-febrile neutropenia, and 1 (4%)-infection; grade 3 toxicities were 4 (15%)-neutropenia, 4 (15%)-fatigue, 2 (7%)-neuropathy, 2 (7%)-athralgias, 2 (7%)-stomatitis, 1 (7%)-pleural effusion, and 1 (4%)-hypertension.
  • In hypothesis-generating univariate and limited multivariate analyses, E-selectin was statistically significantly associated with response to the combination.
  • Additional studies evaluating E-selectin as a marker of response to bevacizumab-containing chemotherapy are warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers, Tumor / analysis. Disease Progression. Drug Administration Schedule. Female. Humans. Middle Aged. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707611.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Taxoids; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


8. Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW: First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res; 2007 Feb 15;13(4):1238-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To test the tolerability, safety, and recommended phase II dose of CP-724,714, a reversible, highly selective, oral HER2 tyrosine kinase inhibitor in patients with advanced solid tumor malignancies that express HER2.
  • EXPERIMENTAL DESIGN: A phase I trial evaluated escalating doses of CP-724,714, administered daily in 21-day cycles.
  • Pharmacokinetics/pharmacodynamics were evaluated in serial blood samples and in pretreatment and posttreatment tumor and skin biopsies.
  • Dosing at 400 mg twice daily and 250 mg thrice daily was not feasible due to reversible, cholestatic liver dysfunction.
  • Treatment-related adverse events were nausea (58%), asthenia (23%), hyperbilirubinemia (27%), elevated transaminases (30%), and skin rash (30%); neither diarrhea nor cardiomyopathy was observed.
  • No objective responses were observed in 28 evaluable patients; 8 (29%) patients had stable disease.
  • Twenty-seven (96%) patients received prior trastuzumab and were heavily pretreated (median prior chemotherapy, 6; range, 1-11).
  • CONCLUSIONS: Dose-limiting toxicities included hyperbilirubinemia, elevated alanine aminotransferase, thrombocytopenia and pulmonary embolus.
  • Although the protocol-specified maximum tolerated dose of CP-724,714 was 250 mg thrice daily, the recommended phase II dose was 250 mg twice daily due to excessive late-cycle hepatotoxicity.
  • Despite extensive prior treatment, 29% of patients had stable disease.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Neoplasms / drug therapy. Neoplasms / enzymology. Protein Kinase Inhibitors / adverse effects. Protein Kinase Inhibitors / pharmacokinetics. Quinazolines / adverse effects. Quinazolines / pharmacokinetics. Receptor, ErbB-2 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317835.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


9. Klepacka T, Woźniak W, Liebhart M, Michalak E, Kuczabski M, Rychłowska M: [Local recurrences after salvage operations in the therapy of osteogenic sarcoma cases - an analysis of adverse effects based on studied cases]. Med Wieku Rozwoj; 2000 Apr-Jun;4(2 Suppl 2):67-76
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrences after salvage operations in the therapy of osteogenic sarcoma cases - an analysis of adverse effects based on studied cases].
  • Therapeutic approach in osteogenic sarcoma until 1982 was connected mainly with surgery.
  • Introduction of chemotherapy to the therapeutic protocols of osteogenic sarcoma improved the 5 years survival of patients with osteogenic sarcoma from 20% to 60-70%.
  • The approach to surgical treatment was also changed.
  • The principle of this treatment is usually to perform an operation to spare the limb with an intraoperative frozen section examination of bone marrow.
  • In our Institute during the last 14 years about 300 cases were diagnosed, out of which about 200 were treated surgically, among these about 50% underwent treatment by salvage operations.
  • Only in 7 cases local recurrences of disease were confirmed.
  • Five of these cases were tumours of distal metaphysis of the femur, one case of proximal metaphysis of the tibia and one case of proximal metaphysis of the humeral bone.
  • The sex range M/F was: 5/2, the average age of onset about 14 years.
  • Various factors playing a role in therapeutic adversities were analysed.
  • Among these were: radical surgery, grade of differentiation of the tumour, histological subtype, soft tissue infiltration, reaction to preoperative therapy and the type of chemotherapy.
  • The conducted analysis indicates the role played by sparing surgery in adversities in therapy (3 cases).
  • Attention was also given to the distinct tendency of osteogenic sarcoma to produce vascular embolism which is a source of haematogenously spreading metastases.
  • In 7 cases vascular tumour embolism caused the appaerance of metastatic focuses adjacent to the primary tumour.
  • A certain role in therapeutic adverities is played by the lack of response to preoperative chemotherapy (4/7 cases).
  • [MeSH-major] Bone Neoplasms / surgery. Neoplasm Recurrence, Local. Osteosarcoma / surgery. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Female. Humans. Male. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11178330.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Kosugi M, Ono T, Yamaguchi H, Sato N, Dan K, Tanaka K, Takano T: Successful treatment of primary cardiac lymphoma and pulmonary tumor embolism with chemotherapy. Int J Cardiol; 2006 Jul 28;111(1):172-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary cardiac lymphoma and pulmonary tumor embolism with chemotherapy.
  • A 72-year-old man with a large mass in the right atrium and the pulmonary embolism by chest computed tomography was diagnosed as the primary cardiac B-cell lymphoma (PCL) with pulmonary tumor embolism and pericardial effusion.
  • Upon completion of initial chemotherapy, the mass was markedly reduced, and the pulmonary embolism disappeared on magnetic resonance imaging.
  • This rarely diagnosed entity is treatable with chemotherapy for both PCL and pulmonary embolism.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Neoplastic Cells, Circulating. Pulmonary Embolism / drug therapy. Pulmonary Embolism / etiology
  • [MeSH-minor] Aged. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129500.001).
  • [ISSN] 0167-5273
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


11. Ishiko T, Doi K, Beppu T, Hirota M, Ogawa M: [A case report of advanced huge hepatocellular carcinoma (H.C.C.) accompanied by tumor embolism to the inferior caval vein (Vv3) that was treated with surgical extended right lobectomy after multimodal therapy]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2416-20
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of advanced huge hepatocellular carcinoma (H.C.C.) accompanied by tumor embolism to the inferior caval vein (Vv3) that was treated with surgical extended right lobectomy after multimodal therapy].
  • We performed multimodal therapy for a huge hepatocellular carcinoma with tumor embolism (Vv3), for which excision was judged impossible.
  • After treatment, a hepatectomy to the primary lesion was finally carried out and long-term survival was achieved.
  • A 52-years-old man with right lateroabdominal pain had a huge occupied hepatocellular carcinoma that was detected in October 2000.
  • A tumor embolism, which invaded the inferior vena cava, was also seen.
  • A percutaneous transhepatic portal embolism (PTPE) was carried out against the right portal vein to increase in the left lobe capacity.
  • The chemo-radiotherapy (36 Gy to the right hepatic vein and systemic administration of CDDP) and transcatheter arterial chemoembolization were added to the feeding arteries of the hepatic tumor.
  • When a decrease in the postcaval vein tumor embolism was observed, the extended right hepatic lobectomy was performed.
  • The postoperative course was good, and the patient was discharged from the hospital on postoperative day 41.
  • Though lung metastasis and new lesions in left lobe were seen in a recurrence, two years and ten months since the start of the systemic chemotherapy.
  • This case suggested that even if a huge liver cancer with vascular invasion is judged impossible to excise, multimodal therapy with the aim of surgical treatment helps retain the possibility to later chose hepatectomy for the primary lesion and improve prognosis.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Hepatectomy. Liver Neoplasms / therapy. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Embolization, Therapeutic. Humans. Male. Middle Aged. Vena Cava, Inferior / pathology

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484089.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Ye Y, Tellez JD, Durazo M, Belcher M, Yearsley K, Barsky SH: E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking. Anticancer Res; 2010 Oct;30(10):3903-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking.
  • E-Cadherin functions as a tumor suppressor in some invasive breast carcinomas and metastasis is promoted when its expression is lost.
  • It has been observed, however, that in one of the most aggressive human breast cancers, inflammatory breast cancer (IBC), E-cadherin is overexpressed and this accounts for the formation of the lymphovascular embolus, a structure efficient at metastasis and resistant to chemotherapy through unknown cytoprotective mechanisms.
  • Studies using a human xenograft model of IBC, MARY-X, indicate that the mechanism of E-cadherin overexpression is not transcriptional but related to altered protein trafficking.
  • By real-time RT-PCR, E-cadherin transcript levels in MARY-X were 3- to 11-fold less than in other E-cadherin positive human breast carcinoma lines but the protein levels were 5- to 10-fold greater.
  • A real-time RT-PCR screen of candidate molecules generally known to regulate protein trafficking was conducted.
  • The screen revealed 3.5- to 7-fold increased ExoC5 level and 10 to 20 fold decreased HRS and RAB7 levels, which was confirmed in human microdissected lymphovascular emboli.
  • Since these alterations may only be correlative with E-cadherin overexpression, one of the molecules, Rab7, was selectively knocked down in MCF-7 cells.
  • An increase in the full length 120 kDa E-cadherin and the de novo appearance of the 95 KD band were observed.
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Lymphatic Vessels / metabolism. Lymphatic Vessels / pathology. Mice. Mice, Nude. Mice, SCID. Neoplastic Cells, Circulating / metabolism. Neoplastic Cells, Circulating / pathology. Protein Transport. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Spheroids, Cellular / metabolism. Spheroids, Cellular / pathology

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036701.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  •  go-up   go-down


13. Dickler M, Rugo H, Caravelli J, Brogi E, Sachs D, Panageas K, Flores S, Moasser M, Norton L, Hudis C: Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol; 2004 Jul 15;22(14_suppl):2001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2001 Background: Aberrant VEGFR expression in breast tumor cells and EGFR expression in endothelial cells may contribute to tumor growth and progression (Baker, 2002; Kranz, 1999).
  • Preclinical evidence suggests that EGFR blockade may inhibit angiogenesis (Hirata, 2002), and combined blockade of the VEGFR and EGFR pathways may increase anti-tumor activity in xenograft models (Jung, 2002).
  • We performed this two stage phase II study to explore the activity of erlotinib and bevacizumab in MBC, as a phase I/II trial in lung ca showed no pharmacokinetic interaction (Mininberg, ASCO 2003).
  • METHODS: Erlotinib (150 mg orally/day) and bevacizumab (15mg/kg IV q3 weeks) is given to pts with measurable MBC following 1-2 prior chemotherapy regimens (CRx).
  • The primary endpoint is response rate; secondary endpoints include safety and time to tumor progression.
  • Markers of the EGFR and VEGFR pathways will be evaluated in archival tumor tissue and in pre/post treatment tumor biopsies in several pts.
  • Pts received a total of 38 cycles of study therapy, with median of 2 cycles/pt (range 1-9).
  • Response is evaluable in 9 pts (75%), with 3 pts too early for response assessment.
  • One pt had a confirmed PR (11%), 2 had SD at 9 wks (22%), 5 had POD (56%), and 1 (11%) came off study after 1 cycle due to an allergic drug eruption.
  • Two pts (15%) experienced grade (gr) 4 toxicities: pulmonary embolus 1 (8%) and neutropenia 1 (8%).
  • CONCLUSIONS: Activity in the first stage of this phase II trial justifies expanded study of erlotinib and bevacizumab in MBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015792.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sherman EJ, Fury MG, Tuttle RM, Ghossein R, Stambuk H, Baum M, Lisa D, Su YB, Shaha A, Pfister DG: Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6059 Background: Historically, systemic therapy for radioactive iodine (RAI)-refractory thyroid cancer has been understudied.
  • Available drugs have modest efficacy.
  • Depsipeptide (DEP) is a histone deacetylase inhibitor with potent anti-tumor effects both in vitro and in vivo.
  • METHODS: Eligible patients (pts) must have progressive, RAI-refractory, recurrent/metastatic, non-medullary, non-anaplastic thyroid cancer; RECIST measurable disease; and adequate organ/marrow function.
  • Exclusionary criteria include prior chemotherapy in the recurrent/metastatic setting; cardiac disease or dysfunction; QTc prolongation or co-administration of drugs that prolong the QTc.
  • The primary endpoint is response rate by RECIST criteria; change in RAI avidity is a secondary endpoint.
  • Grade 4-5 AE possibly related to drug: grade 5 sudden death (1); grade 4 -pulmonary embolus (1).
  • Evaluation of response: stable disease (10); progression (3); early death (1); unknown/inevaluable (6: 5 - temporary protocol suspension; 1 - withdrew consent).
  • For evaluable patients (14) only, median overall survival and time on study was 36 (.5-45+) months and 1.7 (0.46-12) months, respectively.
  • CONCLUSIONS: We observed preliminary signs of in vivo reversal of RAI resistance after treatment with DEP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961936.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Janne PA, Reckamp K, Koczywas M, Engelman JA, Camidge DR, Rajan A, Khuri F, Liang JQ, O'Connell J, Giaccone G: Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):8063

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial.
  • : 8063 Background: Options are limited for pts with NSCLC following chemotherapy and E.
  • Based on non-clinical and phase I NSCLC data, this ongoing phase II U.S. trial evaluates PF299 in pts with NSCLC (KRAS wild-type) who have progressive disease after at least 1 prior chemotherapy regimen and after E.
  • Tissue and blood KRAS assays, and EGFR studies on available tissue, are also being performed.
  • RESULTS: Thirty-four pts with progressive NSCLC (25 female, 14 smoker) have enrolled to date (Arm A: 30; Arm B: 4): median duration of prior E: 11.5 months; median time since E: 2.5 months.
  • Among 20 response-evaluable pts, stable disease (SD) was observed in 9/18 pts in Arm A, and 1/2 pts in Arm B: median duration of SD: 11.5 weeks [range 6+, 32+ weeks].
  • Observation of disease control included pts who had recently (≤8 weeks) discontinued E; and also pts whose tumor had known EGFR T790M mutations.
  • At time of data cutoff, confirmation per RECIST of 2 partial responses is pending.
  • The most common treatment-related AEs were skin and gastrointestinal disorders, with grade 3 AEs in 19% and 13% of pts, respectively.
  • Two pts experienced grade 4 pulmonary embolus/dyspnea deemed possibly treatment-related, both in the setting of progressive disease.
  • CONCLUSIONS: PF299 shows encouraging activity in NSCLC pts after failure of prior chemotherapy and E.
  • At submission, enrollment in the adenocarcinoma arm is complete and enrollment in the non-adenocarcinoma arm continues; updated efficacy data and tumor characterization will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962636.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Schneider BJ, Bradley D, Smith DC, Egorin M, Kalemkerian G, Dunn R, Daignault S, Hussain M: Phase I study of vorinostat plus docetaxel in patients with solid tumor malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):2528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of vorinostat plus docetaxel in patients with solid tumor malignancies.
  • METHODS: Eligible pts had castration-resistant prostate cancer (CRPC) or relapsed urothelial or non-small-cell lung cancer (NSCLC) after ≥1 prior chemotherapy regimen not containing docetaxel, a performance status of 0-2 and adequate organ function.
  • Vorinostat was given orally for 14 days beginning on day 1 of a 21-day cycle.
  • Docetaxel was given intravenously over 1 hour on day 4.
  • The time-to-event continuous reassessment method guided dose escalation.
  • Blood was collected on days 1 and 4 of cycle 1 to measure drug levels by HPLC.
  • RESULTS: 12 pts were enrolled: median age 65 yrs (49-74); gender 9M:3F; 4 CRPC, 5 urothelial, 3 NSCLC.
  • Other toxicities included grade 4 neutropenia (n = 2), pulmonary embolus (n = 1) and GI bleed (n = 1).
  • PK analysis will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961839.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hiraki M, Sato S, Kai K, Ohtsuka T, Kohya N, Kitajima Y, Nakafusa Y, Tokunaga O, Miyazaki K: A long-time survivor of alpha-fetoprotein-producing gastric cancer successfully treated by fluoropyrimidine-based chemotherapy: a case study. Clin J Gastroenterol; 2009 Oct;2(5):331-337

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-time survivor of alpha-fetoprotein-producing gastric cancer successfully treated by fluoropyrimidine-based chemotherapy: a case study.
  • A 67-year-old male with advanced gastric cancer and lymph node metastasis as well as a tumor embolus in the portal vein was treated by S-1/cisplatin therapy.
  • After one course of chemotherapy, the patient showed stable disease; the serum level of alpha-fetoprotein also decreased to 626 ng/ml after a transient increase, and therefore reduction surgery was performed.
  • A total gastrectomy with a distal pancreatectomy, splenectomy, and regional lymph node dissection was performed.
  • There were no metastatic foci in the resected lymph nodes, presumably due to the preoperative chemotherapy.
  • S-1/cisplatin therapy was continued after the operation to treat the remaining tumor embolus in the portal vein.
  • After one course of this therapy, the tumor embolus disappeared.
  • However, a lymph node measuring 1.5 cm in diameter appeared in the hepatoduodenal ligament.
  • Therefore, the chemotherapy was changed to paclitaxel monotherapy.
  • After 2 courses of paclitaxel monotherapy, the lymph node swelled, and thus 5'-deoxy-5-fluorouridine was added to the paclitaxel regimen.
  • After 5 courses of this regimen, the lymph node swelling disappeared without any other new lesions and a total of 21 courses were performed.
  • The ortate phosphoribosyltransferase expression was strongly positive, and the good outcome in this case may have been associated with this result.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:71-81 [12775024.001]
  • [Cites] World J Surg Oncol. 2007 Jul 16;5:79 [17634124.001]
  • [Cites] Hepatogastroenterology. 2006 May-Jun;53(69):338-41 [16795967.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):326-8 [15783061.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2008 Oct;105(10):1489-95 [18840987.001]
  • [Cites] Acta Gastroenterol Belg. 2006 Jul-Sep;69(3):330-7 [17168134.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] Surg Today. 2002;32(5):429-33 [12061695.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):138-44 [15827767.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2495-501 [15330204.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):416-9 [9708646.001]
  • [Cites] Intern Med. 2000 Mar;39(3):223-7 [10772124.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1300-6 [9762929.001]
  • [Cites] Radiology. 1990 Mar;174(3 Pt 1):811-4 [1689502.001]
  • [Cites] Kurume Med J. 2002;49(3):157-60 [12471731.001]
  • [Cites] Dig Surg. 2002;19(5):359-65; discussion 365 [12435906.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:66-70 [12775023.001]
  • [Cites] Am J Gastroenterol. 1992 Mar;87(3):321-5 [1371637.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Surg Today. 2004;34(9):784-7 [15338356.001]
  • [Cites] Cancer Lett. 2007 Dec 8;258(1):45-54 [17892912.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Dec;28(13):2079-82 [11791389.001]
  • [Cites] Oncology. 2004;66(6):445-9 [15452373.001]
  • [Cites] Oncol Rep. 2006 Oct;16(4):721-7 [16969485.001]
  • [Cites] Hepatogastroenterology. 2007 Jun;54(76):1302-4 [17629094.001]
  • [Cites] J Gastroenterol. 2003;38(6):540-7 [12825129.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2005 Dec;102(12):1523-8 [16372769.001]
  • [Cites] Oncology. 2004;66(3):226-33 [15218314.001]
  • [Cites] Intern Med. 2004 Feb;43(2):106-10 [15005251.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1927-33 [16736497.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Feb;35(2):299-301 [18281769.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Jun;32(6):855-8 [15984531.001]
  • [Cites] Surg Today. 2002;32(12 ):1075-80 [12541026.001]
  • (PMID = 26192608.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemoresistance / Dihydropyrimidine dehydrogenase / Ortate phosphoribosyltransferase / Thymidylate synthase
  •  go-up   go-down


18. Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst; 2009 Aug 5;101(15):1049-57
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
  • BACKGROUND: Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor.
  • We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance treatment.
  • METHODS: A total of 724 patients (51% with limited and 49% with extensive disease) were randomly assigned to receive placebo or thalidomide capsules, 100-200 mg daily for up to 2 years.
  • Endpoints were overall survival, progression-free survival, tumor response rate, toxicity, and quality of life (QoL).
  • RESULTS: The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 1.09, 95% confidence interval [CI] = 0.93 to 1.27; P = .28).
  • Among patients with limited-stage disease, there was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15), but among patients with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 to 1.68).
  • Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; P < .001).
  • There were no statistically significant differences between treatments in hematological and nonhematological toxic effects, except more patients in the thalidomide group had rash, constipation, or neuropathy.
  • Overall, QoL scores were similar in the two treatment groups, but thalidomide was associated with less insomnia and diarrhea and more constipation and peripheral neuropathy.
  • CONCLUSIONS: In this large randomized trial, thalidomide in combination with chemotherapy did not improve survival of patients with SCLC but was associated with an increased risk of thrombotic events.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Small Cell Lung Carcinoma / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Double-Blind Method. Drug Administration Schedule. Female. Great Britain. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Quality of Life. Research Design. Thrombosis / chemically induced. Treatment Failure

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2009 Aug 5;101(15):1034-5 [19608998.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Dec 2;101(23):1657; author reply 1657-8 [19858426.001]
  • (PMID = 19608997.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C1438/A2932
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


19. Mori M, Tsukahara F, Yoshioka T, Irie K, Ohta H: Suppression by 17beta-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors. Life Sci; 2004 Jun 18;75(5):599-609
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several observational studies have shown that estrogen replacement therapy decreases cardiovascular mortality and morbidity in postmenopausal women.
  • However, The Women's Health Initiative (WHI) study has found that women receiving estrogen plus progestin had a significantly higher risk of breast cancer, coronary heart disease, stroke, and pulmonary embolus.
  • Treatment with tumor necrosis factor (TNF)-alpha increased expression of vascular cell adhesion molecule (VCAM)-1 mRNA, activation of nuclear factor-kappaB (NF-kappaB), and U937 cell adhesion in ECV304 cells.
  • These effects of TNF-alpha were not significantly inhibited by pretreatment of native ECV304 cells with 17beta-estradiol (E(2)).
  • E(2) may prevent plaque formation, as first stage of atheroscrelosis through inhibiting adhesion monocytes to endothelial cell.
  • Actions of estrogen replacement therapy can be assessed in terms of densities of functional ERalpha.
  • [MeSH-major] Endothelium, Vascular / drug effects. Estradiol / pharmacology. Monocytes / drug effects. Receptors, Estradiol
  • [MeSH-minor] Cell Adhesion / drug effects. Cell Adhesion / physiology. Cell Line. Dose-Response Relationship, Drug. Gene Expression Regulation / drug effects. Humans. NF-kappa B / biosynthesis. NF-kappa B / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Necrosis Factor-alpha / pharmacology. U937 Cells / drug effects. U937 Cells / physiology. Up-Regulation. Vascular Cell Adhesion Molecule-1 / genetics. Vascular Cell Adhesion Molecule-1 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15158369.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / RNA, Messenger; 0 / Receptors, Estradiol; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Cell Adhesion Molecule-1; 4TI98Z838E / Estradiol
  •  go-up   go-down


20. Ramos M, Benavente S, Giralt J: Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations. Expert Rev Anticancer Ther; 2010 Mar;10(3):339-44
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations.
  • Risk factors for adjuvant radiotherapy are stage III-IV, perineural involvement or vascular tumor embolism.
  • For patients with nonresectable disease we recommend treatment with concomitant chemoradiation, although this has important acute and late toxicity.
  • Concomitant EGF receptor inhibitors and taxane-based induction chemotherapy are new strategies under study that have demonstrated some benefits but are not yet the standard treatment.
  • Intensity-modulated radiotherapy allows one to decrease radiation dose to organs.
  • Preclinical work in signaling pathways and other oncogenic factors (e.g., human papillomavirus infection) will be the key to improving outcomes of head and neck cancer patients in the future.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Europe / epidemiology. Humans. Neoplasm Staging. Practice Guidelines as Topic. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Radiotherapy, Intensity-Modulated / methods. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20214515.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


21. Tanoue Y, Tanaka N, Suzuki Y, Hata S, Yokota A: A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism. World J Gastroenterol; 2009 Jan 14;15(2):248-51
Genetic Alliance. consumer health - Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism.
  • We report a case of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein (IMV) tumor embolism.
  • We performed colonoscopy, computed tomography and positron emission tomography, which disclosed sigmoid colon cancer with IMV tumor embolism.
  • She underwent sigmoidectomy and lymph node dissection.
  • The tumor was diagnosed as endocrine cell carcinoma (type 4, pSS, med, INFalpha, v3, n1, stage IIIb).
  • She was treated with chemotherapy of cisplatin (CDDP) + irinotecan (CPT11).
  • This case highlights the aggressiveness of endocrine cell carcinoma with tumor embolism, and it is essential to establish an accurate diagnosis and effective treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Gastric Cancer. 2003;6(4):203-9 [14716513.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Cancer Res. 1983 May;43(5):2088-93 [6187442.001]
  • [Cites] Surg Today. 2007;37(11):989-94 [17952533.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):315-21 [1847579.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Pathol Int. 1995 Aug;45(8):605-9 [7496507.001]
  • [Cites] South Med J. 1996 Sep;89(9):921-4 [8790320.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):135-40 [2293859.001]
  • (PMID = 19132778.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2653316
  •  go-up   go-down


22. Arizpe-Bravo AB, García-Méndez J, Baltazares-Lipp E: Catheter-related septic thrombophlebitis of the great central veins successfully treated with low-dose streptokinase thrombolysis and antimicrobials. Thromb J; 2005 Aug 22;3:11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Septic thrombophlebitis is an iatrogenic life-threatening disease associated with use of central venous devices and intravenous (IV) therapy.
  • In cancer patients receiving chemotherapy, vein resection or surgical thrombectomy in large central venous lines is time-consuming, can delay administration of chemotherapy, and therefore can compromise tumor control.
  • No surgical procedure was needed, and potential placement of a catheter in the same vein was permitted.
  • CONCLUSION: Thrombolysis with streptokinase solved symptoms, cured infection, prevented embolus, and in all cases achieved complete thrombus lysis, avoiding permanent central-vein occlusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1987 Apr;5(4):672-8 [3559656.001]
  • [Cites] Tech Vasc Interv Radiol. 2001 Jun;4(2):127-30 [11981800.001]
  • [Cites] JAMA. 1994 Apr 6;271(13):1014-6 [8139059.001]
  • [Cites] West J Med. 1986 Aug;145(2):200-3 [3765599.001]
  • [Cites] J Vasc Interv Radiol. 2001 Aug;12(8):951-5 [11487675.001]
  • [Cites] Klin Padiatr. 1991 Sep-Oct;203(5):363-5 [1942943.001]
  • [Cites] Medicine (Baltimore). 1985 Nov;64(6):394-400 [3932817.001]
  • [Cites] Am J Med. 1998 Nov;105(5):446-50 [9831430.001]
  • [Cites] Surgery. 1995 Jul;118(1):49-53 [7604379.001]
  • [Cites] J Vasc Surg. 1986 Dec;4(6):606-11 [3783835.001]
  • [Cites] J Thromb Haemost. 2005 Nov;3(11):2409-19 [15975139.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2655-60 [15837979.001]
  • [Cites] Am J Surg. 1993 Dec;166(6):716-8; discussion 718-9 [8273856.001]
  • [Cites] Rev Med Interne. 1996;17(10):821-5 [8976975.001]
  • [Cites] Arch Intern Med. 1980 Oct;140(10):1370-1 [6775611.001]
  • [Cites] Am J Med. 1986 Aug;81(2):351-4 [3090881.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 1989 Jan-Feb;13(1):92-8 [2494373.001]
  • (PMID = 16111500.001).
  • [ISSN] 1477-9560
  • [Journal-full-title] Thrombosis journal
  • [ISO-abbreviation] Thromb J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1236965
  •  go-up   go-down


23. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA: A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer; 2005 Apr;6(1):55-60
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study was designed to evaluate the efficacy and safety of single-agent gemcitabine for the treatment of patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC).
  • Eligible patients were required to have bidimensionally measurable MBC that had been treated with 2-4 prior chemotherapy regimens that included an anthracycline and a taxane.
  • Gemcitabine was delivered at a dose of 800 mg/m2 on days 1, 8, and 15 of a 28-day cycle until evidence of disease progression.
  • PATIENTS AND METHODS: Twenty-two patients were enrolled and included in the safety analysis; 18 patients were evaluable for response.
  • The mean number of prior chemotherapy regimens for metastatic disease was 2.3, and the mean dose of gemcitabine delivered was 911 mg/m2 (range, 600-1600 mg/m2).
  • RESULTS: Overall, gemcitabine was well tolerated with minimal grade 3 toxicities; the only grade 4 toxicity was 1 case of pulmonary embolus.
  • Three patients had evidence of partial tumor regression (17%; 95% CI, 4%-41%), and 1 patient had a 41% decrease in tumor volume, including liver metastasis.
  • The activity and safety reported in this trial are consistent with previous reports in similar patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Anthracyclines / administration & dosage. Bridged Compounds / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Middle Aged. Nausea / chemically induced. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Skin Neoplasms / secondary. Soft Tissue Neoplasms / secondary. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome. Vomiting / chemically induced


24. Sentani K, Nakanishi Y, Ojima H, Hamaguchi T, Shimoda T: Esophageal squamous cell carcinoma presenting with systemic arterial embolism. Pathol Int; 2007 Feb;57(2):96-100
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal squamous cell carcinoma presenting with systemic arterial embolism.
  • Acute arterial occlusion as a result of embolization from a malignant tumor is rare and infrequently reported.
  • Recently a 70-year-old man initially presented with acute arterial occlusion of the left lower limb.
  • He underwent embolectomy, and embolus was diagnosed as a squamous cell carcinoma histologically.
  • Subsequent upper gastrointestinal endoscopy showed superficial esophageal cancer in the thoracic esophagus.
  • Although scheduled to undergo chemotherapy, he died of acute pneumonia on the 81st day from onset.
  • Autopsy showed superficial esophageal cancer, measuring 1.5 cm in diameter, and widespread tumor extension into arterial vessels such as the left femoral artery, the superior mesenteric artery, bilateral intrapulmonary arteries and veins such as bilateral brachiocephalic vein to the supra vena cava, despite small tumor size and shallow tumor invasion depth of the submucosal layer.
  • This case is particularly interesting because the cancer manifested as arterial cancer embolism.
  • [MeSH-minor] Aged. Diagnosis, Differential. Femoral Artery / pathology. Humans. Male. Mesenteric Artery, Superior / pathology. Pulmonary Artery / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300674.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 17
  •  go-up   go-down


25. Patel VG, Eltayeb OM, Henderson VJ, Lyons R, Martin D, Hamami A, Fortson JK, Weaver WL: Primary duodenal low-grade mucosa-associated lymphoid tissue lymphoma presenting with outlet obstruction. Am Surg; 2004 Jul;70(7):613-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary duodenal low-grade mucosa-associated lymphoid tissue lymphoma presenting with outlet obstruction.
  • Low-grade lymphoma arising in mucosa-associated lymphoid tissue (MALT) of the duodenum represents a very rare neoplasm.
  • We report an unusual presentation of primary duodenal MALT lymphoma in a 78-year-old man.
  • The patient initially presented with a suspected pulmonary embolus and was anticoagulated, which precipitated a major gastrointestinal hemorrhage.
  • An endoscopic retrograde cholangiopancreatography (ERCP) was performed, which revealed a normal pancreatic duct with a large calculus in the common bile duct, which was extracted after sphincterotomy.
  • The patient developed severe nausea, vomiting, and fullness after meals.
  • Celiac, peripancreatic, pelvic, and cervical nodes were also involved with tumor.
  • Bone marrow was also positive for metastasis.
  • The patient was postoperatively treated with chemotherapy for stage IV disease.
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15279185.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Mehta RS, Schubbert T, Marshall J, Carpenter PM: Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli. Clin Breast Cancer; 2009 Feb;9(1):56-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.
  • We demonstrate successful treatment of recurrent chondroid-metaplastic breast cancer.
  • Breast cancer recurrence was diagnosed when a patient with a history of metaplastic breast cancer presented with recurrent acute strokes.
  • A diagnosis of tumor embolism was suspected when a chest radiograph performed as part of a work-up for stroke demonstrated several lung nodules, with 1 lung nodule invading the pulmonary vein and extending into the left atrium-the source of tumor emboli.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Metaplasia / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Albumin-Bound Paclitaxel. Albumins / administration & dosage. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299243.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA062203
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumin-Bound Paclitaxel; 0 / Albumins; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Shamberger RC, Ritchey ML, Haase GM, Bergemann TL, Loechelt-Yoshioka T, Breslow NE, Green DM: Intravascular extension of Wilms tumor. Ann Surg; 2001 Jul;234(1):116-21
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular extension of Wilms tumor.
  • OBJECTIVE: To define the incidence and manifestations of and optimal therapy for children with intravascular extension of Wilms tumor.
  • METHODS: Children on a collaborative study of Wilms tumor who had intravascular extension into the inferior vena cava (IVC) or atrium were identified.
  • RESULTS: One hundred sixty-five of 2,731 patients had intravascular extension of Wilms tumor.
  • Sixty-nine had received preoperative therapy (55 with IVC extension and 14 with atrial extension) for a median of 8 weeks.
  • Complications during preoperative chemotherapy were seen in five patients (tumor embolism and tumor progression in one each, and three with adult respiratory distress syndrome, one of which was fatal).
  • The intravascular extension of the tumor regressed in 39 of 49 children with comparable pre- and posttherapy radiographic studies, including 7 of 12 in whom the tumor regressed from an atrial location, thus obviating the need for cardiopulmonary bypass.
  • Surgical complications occurred in 36.7% of the children in the atrial group and 17.2% in the IVC group.
  • The frequency of surgical complications was 26% in the primary resection group versus 13.2% in children with preoperative therapy.
  • When all the complications of therapy were considered, including those that occurred during the interval of preoperative chemotherapy (one of the five also had a surgical complication), the incidence of complications among those receiving preoperative therapy was not statistically different from the incidence among those who underwent primary resection.
  • The difference in 3-year relapse-free survival (76.9% for 165 patients with intravascular extension, 80.3% for 1,622 patients with no extension) was not statistically significant whether or not it was adjusted for stage and histology.
  • CONCLUSIONS: Preoperative treatment of these children may facilitate resection by decreasing the extent of the tumor thrombus, but the overall frequency of complications is similar in both groups.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1970 Aug;26(2):338-40 [4317965.001]
  • [Cites] J Urol. 1988 Nov;140(5 Pt 2):1113-8 [2846897.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Spring;8(1):75-8 [3013040.001]
  • [Cites] Med Pediatr Oncol. 1992;20(1):61-3 [1309207.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):912-5 [1322458.001]
  • [Cites] Surg Gynecol Obstet. 1992 Dec;175(6):507-14 [1333095.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4104-10 [8389661.001]
  • [Cites] J Urol. 1993 Sep;150(3):933-5 [8393945.001]
  • [Cites] J Pediatr Surg. 1994 Feb;29(2):229-31 [8176597.001]
  • [Cites] Pediatr Hematol Oncol. 1994 Sep-Oct;11(5):535-40 [7530031.001]
  • [Cites] Med Pediatr Oncol. 1996 Apr;26(4):268-71 [8600341.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):772-6 [8976777.001]
  • [Cites] Postgrad Med J. 1996 Dec;72(854):749-50 [9015469.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):237-45 [9440748.001]
  • [Cites] J Urol. 1986 Jul;136(1 Pt 2):312-7 [2425100.001]
  • [Cites] Ann Surg. 1986 Dec;204(6):693-7 [3024596.001]
  • [Cites] Urology. 1982 Jan;19(1):55-60 [6277066.001]
  • (PMID = 11420491.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-42326
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1421956
  •  go-up   go-down


28. Tsuchiya T, Hiramatsu K, Tanaka H, Machiki Y, Sakuragawa T, Otsuji H, Hara T, Kimura A, Yoshida K, Hosoya J, Kojima T, Kato K: [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2641-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
  • A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion.
  • A 69-year-old man was admitted to our hospital with severe anemia.
  • He was diagnosed with advanced gastric cancer, T3N1H0P0M0, Stage IIIa.
  • Total gastrectomy with pancreato-splenectomy with D2 lymph node dissection was done for curative resection.
  • Seven months after operation, recurrent liver metastases with tumor embolism of the portal vein were revealed by enhanced CT examination.
  • FU (5-FU/UFT) +CPT-11 was done as the first-line adjuvant chemotherapy.
  • Metastatic lesion of the liver and portal vein tumor embolism was decreased.
  • Tumor marker CA19-9 level was also decreased and within normal limits.
  • This therapy was evaluated as a partial response (PR) in twelve months and the patient died three years and eight months after operation.
  • Gastric endocrine cell carcinoma is known as a potentially highly malignant tumor.
  • But in our case FU+CPT-11 controlled growth of the recurrent tumor.
  • Based on this finding, we recommend adjuvant chemotherapy by FU+CPT-11 for gastric endocrine cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Gastrectomy. Humans. Lymph Node Excision. Male. Neoplasm Metastasis. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009471.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


29. Tucakovic M, Bascom R, Bascom PB: Pulmonary medicine and palliative care. Best Pract Res Clin Obstet Gynaecol; 2001 Apr;15(2):291-304
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant pleural effusion is a poor prognostic factor: management options include repeated thoracentesis, chemical pleurodesis, symptomatic relief of dyspnoea with oxygen and morphine, and external drainage.
  • Parenchymal metastases are typically multifocal and respond to chemotherapy, with a limited role for pulmonary metastatectomy.
  • Pulmonary tumour embolism is frequently associated with lymphangitic carcinomatosis, and is most common in choriocarcinoma.
  • Thromboembolic disease, associated with the hypercoagulable state of cancer, is treated with anticoagulation.
  • Inferior vena cava filter placement is indicated when anticoagulation cannot be given, or when emboli recur despite adequate anticoagulation.
  • Opiates are effective at relieving dyspnoea associated with effusions, metatases, and lymphangitic tumour spread.
  • Non-pharmacological therapies include energy conservation, home redesign, and dyspnoea relief strategies, including pursed lip breathing, relaxation, oxygen, circulation of air with a fan, and attention to spiritual suffering.
  • Identification and treatment of gastroesophageal reflux, sinusitis, and asthma can improve many patients' coughs.
  • Chest wall pain responds to local radiotherapy, nerve blocks or systemic analgesia.
  • Case examples illustrate ways to address quality of life issues.
  • [MeSH-major] Genital Neoplasms, Female / complications. Genital Neoplasms, Female / therapy. Lung Diseases / etiology. Palliative Care / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Airway Obstruction / therapy. Cough / therapy. Dyspnea / therapy. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Meige Syndrome / surgery. Pleural Effusion, Malignant / therapy. Pulmonary Embolism / diagnosis. Pulmonary Embolism / drug therapy. Quality of Life. Vena Cava Filters

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Harcourt Publishers Ltd.
  • (PMID = 11358403.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


30. Grass H, Schuff A, Staak M, Dienes HR, von Both I: Tumor embolism as a cause of an unexpected death: a case report. Pathol Res Pract; 2003;199(5):349-52
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor embolism as a cause of an unexpected death: a case report.
  • The primary causes of deaths for individuals with rare cancers can be difficult to diagnose clinically.
  • This study analyzes the death of a 45-year-old woman who reportedly died from an acute pulmonary dysfunction.
  • The autopsy revealed a bulky thyroid tumor with venous invasion, leading to a massive pulmonary tumor embolism.
  • Furthermore, microscopy identified the tumor as a rare pleomorphic myxoid sarcoma.
  • Thus, the patient died of a large pulmonary tumor embolism originating from this rare sarcoma, and not of acute pulmonary dysfunction of any other means.
  • [MeSH-major] Cause of Death. Neoplastic Cells, Circulating / pathology. Pulmonary Embolism / etiology. Sarcoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Female. Humans. Middle Aged. Pneumonia / complications. Pneumonia / drug therapy

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12908527.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


31. Carron M, Ori C: Thrombolysis for massive pulmonary tumour embolism in a patient with cavoatrial renal carcinoma. Br J Anaesth; 2008 Aug;101(2):285-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombolysis for massive pulmonary tumour embolism in a patient with cavoatrial renal carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Heart Neoplasms / secondary. Neoplastic Cells, Circulating / drug effects. Pulmonary Embolism / drug therapy. Thrombolytic Therapy / methods
  • [MeSH-minor] Humans. Male. Middle Aged. Tissue Plasminogen Activator / therapeutic use

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18614604.001).
  • [ISSN] 1471-6771
  • [Journal-full-title] British journal of anaesthesia
  • [ISO-abbreviation] Br J Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down






Advertisement